Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F10%3A00044289" target="_blank" >RIV/00216224:14110/10:00044289 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage

Popis výsledku v původním jazyce

The aim of the study was to investigate the DNA polymorphic genotype in MMP2 promoter gene as a potential candidate region for the development of the cutaneous T cell lymphoma (CTCL) andor its progression. A total of 89 Czech patients with CTCL (including 23 patients with large plaque parapsoriasis) were compared to 198 controls. The three selected polymorphisms in the promoter of MMP2 gene were determined using the PCR based methodology with RFLP. In our cohort, the associated GGCCTT MMP2 promoter genotype was highly significantly more frequent in CTCL Ia stage patients compared to patients with parapsoriasis, the tests having high sensitivity and specificity (78%, 83%, resp.). To conclude, use of associated MMP2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design, and prognosis of this serious condition in th

Název v anglickém jazyce

Matrix Metalloproteinase-2 Promoter Genotype as a Marker of Cutaneous T-Cell Lymphoma Early Stage

Popis výsledku anglicky

The aim of the study was to investigate the DNA polymorphic genotype in MMP2 promoter gene as a potential candidate region for the development of the cutaneous T cell lymphoma (CTCL) andor its progression. A total of 89 Czech patients with CTCL (including 23 patients with large plaque parapsoriasis) were compared to 198 controls. The three selected polymorphisms in the promoter of MMP2 gene were determined using the PCR based methodology with RFLP. In our cohort, the associated GGCCTT MMP2 promoter genotype was highly significantly more frequent in CTCL Ia stage patients compared to patients with parapsoriasis, the tests having high sensitivity and specificity (78%, 83%, resp.). To conclude, use of associated MMP2 promoter genotype as a DNA marker might make it possible to distinguish between the patients with parapsoriasis and those with CTCL stage Ia, which could substantially improve possibilities of clinical diagnostics, therapy design, and prognosis of this serious condition in th

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FO - Dermatovenerologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Biomedicine and Biotechnology

ISSN

1110-7243

e-ISSN

—

Svazek periodika

2010

Číslo periodika v rámci svazku

2010:80590

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—